Voyager grants Novartis license to capsid for gene therapy; $15M upfront, up to $305M milestones

Voyager Therapeutics, Inc.

Novartis receives exclusive license to a capsid from Voyager's TRACER platform for a single gene target.
One-time $15M fee paid upfront; Voyager eligible for $130M in development/regulatory/commercial milestones.
Additional sales milestones up to $175M per product plus tiered mid- to high-single-digit royalties.
Novartis' prior option rights for other targets expired as of September 3, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.